HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
AD Drug Development and Animal Models

Alzheimer's disease (AD) is a chronic neurological condition that is regarded as one of the most challenging medical problems to treat, with significant societal and economic consequences. The number of persons living with Alzheimer's disease (AD) in the United States is increasing. Drug discovery in stages of Alzheimer's disease before symptomatic dementia, such as preclinical AD, has resulted from significant research investment. There are now six phase 3 clinical trials for preclinical AD treatments, despite the fact that no medicines for preclinical AD have been approved.

Despite decades of preclinical research to better understand the disease and uncover treatment targets, Alzheimer's disease remains incurable. The challenge is being met with new methods of thinking about a number of animal models. Alzheimer's disease (AD) experimental models are essential for better understanding aetiology and evaluating the efficacy of innovative therapy approaches. Transgenic mice that overexpress human genes linked to familial Alzheimer's disease (FAD) and generate amyloid plaques are the most extensively utilized experimental animal models.

  • Drug Development & Emerging Therapies
  • Aducanumab
  • Drug Design and Discovery
  • Clinical Trials
  • Preclinical Alzheimer Disease Drug Development
  • Experimental Models
Committee Members
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Yong-Xiao Wang

Yong-Xiao Wang

Albany Medical College, United States
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Kaoru Sakatani

Kaoru Sakatani

The University of Tokyo, Japan
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Jun Hua

Jun Hua

Johns Hopkins University School of Medicine, United States

Submit your abstract Today

Watsapp